Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Cana may be able to improve number and function of CD34+
endothelial progenitor cells. The investigators also propose that this expected
cardiovascular benefit is independent of HbA1C reduction.
Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be
withdrawn from the study if the medication or placebo is not tolerated.